Intention-to-treat | Per-protocol | ||||
---|---|---|---|---|---|
Early Rx (n = ) | Expectant (n = ) | Early Rx (n = ) | Expectant (n = ) | ||
Primary composite outcome | |||||
Mortality, BPD and/or NEC at 36 weeks PMA | |||||
Secondary outcomes | |||||
Treatment | Total doses of COXi | ||||
Surgical PDA ligation | |||||
Total fluid intake DOL 7 [ml/kg/day] | |||||
Co-interventions | |||||
Postnatal steroids | |||||
Paracetamol use | |||||
Diuretics | |||||
Death | Mortality at 28 days PNA | ||||
Mortality at 36 weeks PMA | |||||
Mortality | |||||
Haemodynamic | Cardiovascular support | ||||
Volume expansion | |||||
Inotropes/vasopressors | |||||
Corticosteroids | |||||
Hyperlactataemia | |||||
Renal failure | |||||
Hypertension | |||||
Pulmonary | BPD at 28 days PNA | ||||
BPD at 36 weeks PMA | |||||
Supplemental oxygen [days] | |||||
Respiratory support [days] | |||||
Invasive | |||||
Non-invasive | |||||
Pulmonary haemorrhage | |||||
Pulmonary air leakage | |||||
CNS | PVE | ||||
IVH | |||||
Grade I-II | |||||
Grade ≥ III | |||||
PHVD | |||||
Seizures | |||||
GI | NEC (Bell stage ≥ IIa) | ||||
Gastrointestinal haemorrhage | |||||
SIP | |||||
Time to full enteral feeding [days] | |||||
Infection | Sepsis | ||||
Meningitis | |||||
Pneumonia | |||||
Thrombocytopenia | |||||
Hyperglycaemia | |||||
Eye | ROP | ||||
PLUS disease | |||||
ROP treatment | |||||
Miscellaneous | Biometry at PMA 36 weeks | ||||
Weigth [grams] | |||||
Length [cm] | |||||
Biometry at discharge | |||||
Weigth [grams] | |||||
Length [cm] | |||||
Length of hospitalisation [days] | |||||
DA closed at discharge |